COMMUNIQUÉS West-GlobeNewswire

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
14/05/2024
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in [...]
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
14/05/2024
Best Quarterly Results in Company’s History from a Financial Perspective. EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies. Marketing Authorization of Trunerox™ in Colombia by [...]
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
14/05/2024
Cash runway extended into July 2025 from previously April 2025 Capital raise strengthens Medigene’s financial position Lead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024 Use of proceeds [...]
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to [...]
Rejuvine Life Sciences Launches Crowdfunding Campaign to Revolutionize Diabetes Management with Science-Backed, Natural Solutions
14/05/2024
We believe everyone deserves access to safe and effective healthcare solutions. MIDDLETOWN, Del., May 14, 2024 (GLOBE NEWSWIRE) -- via IBN -- Rejuvine Life Sciences , dedicated to developing natural healthcare solutions [...]
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
14/05/2024
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
14/05/2024
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
14/05/2024
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 - The Alliance [...]
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
14/05/2024
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai 2024 – L’Alliance [...]
Periodemeddelelse Første Kvartal 2024
14/05/2024
Selskabet har opnået følgende resultat for første kvartal 2024: EBIT: negativt DKK 0.9 mio. De strategiske partnerskaber har bidraget med en indtægt på DKK 0.6 mio. Egenkapital ultimo marts 2024: DKK 13.4 mio. Business [...]
Coloplast expands its Luja™ portfolio with next generation catheter for women
14/05/2024
The female intermittent catheter enables complete bladder emptying in one free flow 1 , aiming to reduce the risk of urinary tract infections 2 . Following the successful launch of Luja with Micro-hole Zone Technology, [...]
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
14/05/2024
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the [...]
Aino Health AB (publ): interim report january-march 2024
14/05/2024
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Extending existing contracts. Improved cash flow. January – March 2024 • Net sales [...]
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
14/05/2024
GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular [...]
Aurora Spine Corporation Announces First Quarter 2024 Financial Results
14/05/2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a [...]
Pacific Health Care Organization, Inc. Reports its First Quarter 2024 Results
14/05/2024
Irvine, May 13, 2024 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its quarterly report on Form 10-Q [...]
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
14/05/2024
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 [...]
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
14/05/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III [...]

Pages